Register for our free email digests:
Latest From PharmAthene Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.
2016 saw 30 new active substances approved in the EU, in a total of 29 different products, of which 10 were for cancer indications. Also approved were a range of combinations of old and new drugs, some new uses, and a number of biosimilars and generics. 14 of the products approved during the year were for rare diseases, while eight received a conditional marketing authorization.
Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.
- Controlled Release
- Site Specific
- Specialty Pharmaceuticals
- Drug Delivery
- Therapeutic Areas
- Dental & Oral Products
- Infectious & Viral Diseases
- BioAlliance Pharma SA
- Western Europe
- Parent & Subsidiaries
- Onxeo SA
- Senior Management
Judith Greciet, CEO
Nicolas Fellmann, CFO
Aude Michel, Head, Corp. Bus. Dev.
Graham Dixon, PhD, CSO & Head, R&D
- Contact Info
Phone: (33) 1 45 58 76 00
49 boulevard du Général Martial Valin
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.